Sudeep Pharma IPO GMP Today Sees Massive Drop On Last Day Of Subscription; Should You Bid?

Sudeep Pharma IPO GMP Today: The Rs 895 crore initial public offering (IPO) of Sudeep Pharma is all set to close for subscription on Tuesday, November 25. The company's Grey Market Premium (IPO GMP) saw a sharp decline on the final day of subscription.

For investors who are planning to subscribe Sudeep Pharma IPO today, here are all the details they need to know.

Sudeep Pharma IPO Subscription Status Day 3

Sudeep Pharma IPO has been subscribed by 8.44 times on day 3, as per Chittorgarh.com at 11 am. The IPO subscription includes 6.77 times in the retail category, 0.16 times in the QIB category (ex-anchor) and 23.4 times in the NII category.

Sudeep Pharma IPO GMP Today

The company's IPO GMP today saw a sharp decline on Tuesday. Sudeep Pharma IPO GMP today stood at Rs 77, falling sharply from Rs 90 recorded a day ago, according to investorgain.com

Sudeep Pharma IPO's last GMP stood at Rs 77, with the price band of 593 per share. Considering the IPO GMP, its listing price is expected to be Rs 670 per share (which is the sum of upper price band and IPO GMP Today). The expected percentage gain or loss per share is 12.89%.

Investors must note that an IPO GMP indicates the demand for an unlisted company in unregulated grey market, hence it is not a clear indicator of an IPO's listing performance.

Sudeep Pharma IPO GMP Today: Should You Subscribe?

The Vadodara-headquartered company is a leading manufacturer of pharmaceutical excipients and speciality mineral ingredients used across the pharma, food, and nutrition industries. The firm has a strong presence in the industry market and is a leading producer of pharmaceutical, food, nutrition, and speciality ingredients.

Brokerage Anand Rathi has givena 'Subscribe-Long Term' recommendation for Sudeep Pharma IPO. "At the upper price band, the company is valued at 48.3x FY25 P/E, translating to a post-issue market cap of ₹66,979 million. They have also created a wholly owned subsidiary, SAMPL, to leverage their mineral chemistry capabilities in advanced materials, including a new facility for pCAM production beginning with battery-grade iron phosphate for LFP batteries in EVs and energy storage," noted the brokerage in its report.

"The company aims to strengthen its presence in regulated markets such as the US and Europe by capitalizing on USFDA-approved facilities, boosting exports, and transitioning to direct market access supported by local warehousing and sales teams. Given these factors, the IPO appears fully priced, and we assign a "Subscribe - Long Term" rating," the brokerage added.